| Document Date: 2014-12-09 20:31:29
Open Document File Size: 85,86 KBShare Result on Facebook
City Tokyo / / Company Amgen Inc. / Amgen Astellas BioPharma K.K. / Astellas Pharma Inc. / / Country Japan / United States / / Event FDA Phase / Business Partnership / Reorganization / Security Buyback / / / IndustryTerm biologics manufacturing expertise / legislation affecting pharmaceutical pricing / biotechnology / biotechnology pioneer / cell culture systems / trustworthy pharmaceuticals / healthcare cost containment / manufacturing / insurance plans / pharmaceutical / manufacturing problems / manufacturing capacity / / MedicalCondition diabetes complications / tumor / gastric cancer / cancer / disease / infectious diseases / advanced gastric cancer / / MedicalTreatment chemotherapy / / Organization U.S. Food and Drug Administration / U.S. government / RILOMET-1 independent data monitoring committee / Securities and Exchange Commission / / Person Sean E. Harper / / / Position physician / executive vice president of Research and Development / / Product RILOMET-1 / RILOTUMUMAB IN ADVANCED / / ProvinceOrState California / / Technology biotechnology / chemotherapy / transplantation / / URL www.twitter.com/amgen / www.Amgen.com / http /
SocialTag |
T-VEC FDA Filing Acceptance